Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • sibeprenlimab

    - PMLiVE

    Game On: Medscape Education Golfs for a Cause

    Medscape Education is proud to stand alongside the National Kidney Foundation (NKF) as a sponsor of one of the nation’s most impactful charity events benefiting patients living with kidney disease,...

    Medscape Education

    - PMLiVE

    FDA approves Apellis’ Empaveli for two rare kidney diseases

    C3G and primary IC-MPGN are estimated to affect 5,000 people in the US

    - PMLiVE

    Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

    C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

    - PMLiVE

    Otsuka shares promising phase 3 results for sibeprenlimab in rare kidney disease IgAN

    The trial will continue to evaluate change in kidney function over two years

    - PMLiVE

    Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

    Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

    Biogen Idec building

    Biogen initiates phase 3 study of felzartamab in kidney transplant patients

    The trial will evaluate the candidate in patients with antibody-mediated rejection

    - PMLiVE

    Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

    Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

    - PMLiVE

    FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

    The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

    - PMLiVE

    Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

    There are currently no treatments that target the underlying cause of C3G or IC-MPGN

    - PMLiVE

    Novartis’ Fabhalta granted FDA approval for rare kidney disease IgA nephropathy

    Approximately 25 people per million worldwide are diagnosed with IgAN every year

    - PMLiVE

    Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn

    The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria

    - PMLiVE

    Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

    Approximately one to two people per million worldwide are diagnosed with C3G every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links